Pharmaceuticals News and Research

RSS

Unique funding opportunity seeks countermeasures to protect healthy tissue from radiation exposure

Small U.S.-based companies developing countermeasures to protect healthy tissue from the effects of radiation exposures may be eligible for a unique funding opportunity offered through the National Space Biomedical Research Institute. NSBRI's Industry Forum is soliciting applications for its Space Medical and Related Technologies Commercialization Assistance Program (SMARTCAP).

31 Oct 2015

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University.

31 Oct 2015

UCSD researchers develop new computational strategy to find tumor-shrinking molecules

Patients with glioblastoma, a type of malignant brain tumor, usually survive fewer than 15 months following diagnosis. Since there are no effective treatments for the deadly disease, University of California, San Diego researchers developed a new computational strategy to search for molecules that could be developed into glioblastoma drugs. In mouse models of human glioblastoma, one molecule they found shrank the average tumor size by half.

31 Oct 2015

Xcelience announces grand opening of new headquarters in Tampa

Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability services. The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials.

31 Oct 2015

Alexza plans to reacquire U.S. rights for ADASUVE (loxapine) inhalation powder from Teva

Alexza Pharmaceuticals, Inc. announced today that it plans to reacquire the U.S. rights for ADASUVE (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., with an estimated target completion date of January 1, 2016.

31 Oct 2015

NABP report highlights significance of international collaboration in fight against illegal online drug sellers

Today, the National Association of Boards of Pharmacy issued a report discussing the importance of international collaboration in the fight against illegal online drug sellers. As detailed in the Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators: October 2015, there is widespread agreement among multiple countries that Internet sales of medicinal products pose a health risk to their citizens.

31 Oct 2015

Routine clinical features may aid BVFTD diagnostic accuracy

Researchers have identified clinical features that can help determine which patients assessed for behavioural variant frontotemporal dementia are most likely to actually have the condition.

30 Oct 2015

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that INOmax (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for pulmonary hypertension in conjunction with heart surgery.

30 Oct 2015

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders.

30 Oct 2015

Antibiotics have no adverse outcome on child's physical development, shows study

The four out of ten women who use antibiotics during pregnancy can breathe easy, as a comprehensive new study shows that the two most often prescribed drugs have no adverse outcome on the child's physical development.

30 Oct 2015

Novel enzyme therapy offers possible treatment for cocaine overdose

A long-acting enzyme that rapidly and safely metabolizes cocaine in the blood stream is currently being investigated in animal models as a possible treatment for cocaine overdose.

30 Oct 2015

Researchers identify molecular switch that can convert unhealthy white fat into energy-burning brown fat

A research team led by UC San Francisco scientists has identified a molecular switch capable of converting unhealthy white fat into healthy, energy-burning brown fat in mice. Drugs that flip this switch rapidly reduced obesity and diabetes risk factors in mice fed a high fat diet.

30 Oct 2015

New single-agent phototherapy system may form valuable new tool to combat cancer

Researchers at Oregon State University today announced an important advance in the field of cancer imaging and phototherapy, using a single-agent system that may ultimately change the efficacy of cancer surgery and treatment around the world.

30 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Scientists explore biodegradable nanomedicine to destroy ovarian cancer cells left behind after surgery

Scientists are investigating a biodegradable nanomedicine that can selectively destroy ovarian cancer cells left behind after surgery. These findings are a step forward in the development of targeted therapies for hard-to-treat cancers. This work is being presented Oct. 29 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.

29 Oct 2015

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus' UNA Oligomer chemistry and LUNAR nanoparticle delivery platform.

29 Oct 2015

Scientists call for coordinated effort to drive cutting edge microbiome research

A consortium of 48 scientists from 50 institutions in the United States - including Pamela Silver, Ph.D., a Core Faculty member at the Wyss Institute for Biologically Inspired Engineering at Harvard University - are calling for a Unified Microbiome Initiative that would span national cross-institutional and cross-governmental agency support.

29 Oct 2015

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. These results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic. This work is being presented Oct. 28 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.

29 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Pharmaceuticals News and Research

Unique funding opportunity seeks countermeasures to protect healthy tissue from radiation exposure

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

UCSD researchers develop new computational strategy to find tumor-shrinking molecules

Xcelience announces grand opening of new headquarters in Tampa

Alexza plans to reacquire U.S. rights for ADASUVE (loxapine) inhalation powder from Teva

NABP report highlights significance of international collaboration in fight against illegal online drug sellers

Routine clinical features may aid BVFTD diagnostic accuracy

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Antibiotics have no adverse outcome on child's physical development, shows study

Novel enzyme therapy offers possible treatment for cocaine overdose

Researchers identify molecular switch that can convert unhealthy white fat into energy-burning brown fat

New single-agent phototherapy system may form valuable new tool to combat cancer

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Scientists explore biodegradable nanomedicine to destroy ovarian cancer cells left behind after surgery

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Scientists call for coordinated effort to drive cutting edge microbiome research

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Event guide: World ADC London eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring